Mycobactovir for the Treatment of Vulvovaginal Candidiasis: Results from A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial (ex-US)
TGV-Laboratories to Present Results from Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial. Research Presented in a Poster Session at American Society for Microbiology (ASM) Microbe 2018
NEW YORK, NY, June 10, 2018 — TGV-Therapeutics (TGV), a privately held company and our goal is to bring the therapy of invasive fungal infections to a principally new level of the efficacy. The study, coordinated by Drs. V. Tetz and G. Tetz, was presented by Dr. G. Tetz in a poster session at American Society for Microbiology (ASM) Microbe 2018, June 7–11, 2018, in Atlanta
- Data indicates that the antibiotic MYC-053; developed by TGV Therapeutics, has proven effective against the deadly fungal infection Candida auris (C.auris) candidemia.
- Initial testing by TGV was so promising the NIH decided to expand research into MYC-053.
- C.auris is a pathogenic fungus that has been known to spread in healthcare facilities. C.auris can infect wounds, the bloodstream, and the urinary tract.
- The pathogen is extremely dangerous because itis resistant to many existing antifungal drugs.
- MYC-053 is TGV’s lead product candidate, and itis described as a “novel antifungal agent that is structurally distinct fromthe three main classes of antifungal antibiotics.”.
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced today it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.